plerixafor has been researched along with osteoprotegerin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benslimane-Ahmim, Z; Boisson-Vidal, C; Delomenie, C; Fischer, AM; Galy-Fauroux, I; Grelac, F; Heymann, D; Lokajczyk, A; Lutomski, D; Mohamedi, A; Poirier, F | 1 |
| Fu, J; Liu, J; Shen, J; Sun, D; Wang, X; Xie, Z; Yu, S; Zhang, R | 1 |
2 other study(ies) available for plerixafor and osteoprotegerin
| Article | Year |
|---|---|
Mechanistic study of the proangiogenic effect of osteoprotegerin.
Topics: Benzylamines; Caspase 3; Cell Adhesion; Cell Survival; Cyclams; Cytoskeleton; Endothelial Cells; Focal Adhesion Kinase 1; Gene Expression Regulation; Heterocyclic Compounds; Human Umbilical Vein Endothelial Cells; Humans; Integrin alphaVbeta3; Neovascularization, Physiologic; Osteoprotegerin; Phosphorylation; Proteomics; Syndecan-1 | 2013 |
Osteoprotegerin (OPG) Promotes Recruitment of Endothelial Progenitor Cells (EPCs) via CXCR4 Signaling Pathway to Improve Bone Defect Repair.
Topics: Angiogenesis Inducing Agents; Animals; Benzylamines; Bone and Bones; Bone Regeneration; Cell Movement; Cells, Cultured; Chemokine CXCL12; Cyclams; Endothelial Progenitor Cells; Heterocyclic Compounds; Humans; Male; Neovascularization, Pathologic; Osteoprotegerin; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Rats; Rats, Sprague-Dawley; Receptors, CXCR4; Signal Transduction; Stem Cells; Vascular Endothelial Growth Factor A | 2019 |